EUVIMEDEUVIMED entdecken
Crossref

METTL3-Mediated N6-Methyladenosine Modification Regulates the Progression of Diabetic Retinopathy

Huaiyan Jiang, Wenzhong Fu, Yunmin Cai, Hongxia Xu

Applied Biochemistry and Biotechnology · 2025

DOI: 10.1007/s12010-025-05302-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Applied Biochemistry and Biotechnology, 2025. Verfasst von Huaiyan Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, the First Peoples Hospital of Yunnan Province, the Affiliated Hospital of Kunming University of Science and Technology, …. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Methyltransferases, Adenosine, Disease Progression. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Joint Special Fund Project of Yunnan Provincial Science and Technology Department-Kunming Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic retinopathy (DR) is a serious complication associated with diabetes, which may lead to diminished visual acuity or complete loss of sight. N6-methyladenosine (m6A) is recognized as the predominant modification present in eukaryotic mRNAs. However, the role of methyltransferase-like 3 (METTL3)-mediated m6A modification in DR still need further investigation. In our study, we constructed a DR cell model through the application of high glucose (HG) treatment on human retinal microvascular endothelial cells (hRMECs), and we found that METTL3 was downregulated for expression in the DR cell model. Mechanistically, we found that lncRNA MALAT1 was upregulated in hRMECs treated with HG due to the downregulation of METTL3 and subsequent reduction in m6A methylation. Functional experiments demonstrated that HG-induced upregulation of cell viability, endothelial-mesenchymal transition (EndMT), angiogenesis, and inflammatory factors were reversed by overexpressing METTL3, whereas these alleviating effects were neutralized by upregulation of MALAT1. Besides, inhibition of MALAT1 effectively attenuated retinal damage and inflammatory responses in streptozotocin (STZ)-induced DR mice. Furthermore, MALAT1 could act as a microRNA (miR)-23a-3p sponge to increase vascular endothelial growth factor A (VEGFA) expression. Reversal experiments indicated that knockdown of MALAT1 mediated DR alleviation effects were reversed by miR-23a-3p inhibitor or overexpression of VEGFA. In summary, our research findings indicated that silencing METTL3 reduced m6A modification of lncRNA MALAT1 and stabilized MALAT1 expression, thus promoted the growth, EndMT, angiogenesis, and inflammatory response of HG-induced hRMECs through the miR-23a-3p/VEGFA axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyMethyltransferasesAdenosineDisease ProgressionHumansAnimalsMiceRNA, Long NoncodingMicroRNAsEndothelial CellsGlucoseMaleDiabetes Mellitus, ExperimentalMice, Inbred C57BL

Stichwörter der Autor:innen

AngiogenesisDiabetic retinopathyEndothelial–mesenchymal transitionMethyltransferase-like 3N6-Methyladenosine modification

Substanzen

MethyltransferasesAdenosineN-methyladenosineMETTL3 protein, humanRNA, Long NoncodingMicroRNAsMALAT1 long non-coding RNA, humanMettl3 protein, mouseGlucose

Autor:innen und Institutionen

  • Department of Ophthalmology, the First Peoples Hospital of Yunnan Province, the Affiliated Hospital of Kunming University of Science and Technology, No. 157, Jinbi Road, Xishan District, Kunming, 650000, Yunnan, China.
  • Department of Ophthalmology, the Malong District Peoples Hospital, No. 54, Longquan North Road, Malong District, Qujing, Qujing, 655105, Yunnan, China.
  • Department of Ophthalmology, the First Peoples Hospital of Yunnan Province, the Affiliated Hospital of Kunming University of Science and Technology, No. 157, Jinbi Road, Xishan District, Kunming, 650000, Yunnan, China.…

Förderung

  • Joint Special Fund Project of Yunnan Provincial Science and Technology Department-Kunming Medical University

Zitieren

APA

Jiang, H., Fu, W., Cai, Y., & Xu, H. (2025). METTL3-Mediated N6-Methyladenosine Modification Regulates the Progression of Diabetic Retinopathy. Applied Biochemistry and Biotechnology. https://doi.org/10.1007/s12010-025-05302-4

Vancouver

Jiang H, Fu W, Cai Y, Xu H. METTL3-Mediated N6-Methyladenosine Modification Regulates the Progression of Diabetic Retinopathy. Applied Biochemistry and Biotechnology. 2025. doi:10.1007/s12010-025-05302-4

BibTeX
@article{Jiang2025,
  author = {Jiang, Huaiyan and Fu, Wenzhong and Cai, Yunmin and Xu, Hongxia},
  title = {METTL3-Mediated N6-Methyladenosine Modification Regulates the Progression of Diabetic Retinopathy},
  journal = {Applied Biochemistry and Biotechnology},
  year = {2025},
  doi = {10.1007/s12010-025-05302-4}
}
Kostenlos starten →